703 results on '"Carrasquillo, Jorge"'
Search Results
152. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
153. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
154. Feasibility of Administering High-Dose131I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms
155. A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).
156. Alternating increased unilateral vocal cord uptake in a patient with metastatic breast cancer
157. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
158. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates
159. A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.
160. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.
161. Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.
162. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
163. Gallbladder Paraganglioma Associated with SDHDMutation: a Potential Pitfall on 18F-FDOPA PET Imaging
164. Erratum: Radioimmunotherapy of human tumours
165. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.
166. Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.
167. STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).
168. Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.
169. Comparison of 6-[18F]-fluorodopamine positron emission tomography to [123I]-metaiodobenzylguanidine and [111In]-pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma
170. Radioimmunoscintigraphy of lymphoma with monoclonal antibodies
171. ANTIBODY-RADIOISOTOPE CONJUGATES FOR TUMOR LOCALIZATION AND TREATMENT
172. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
173. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
174. Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients
175. Visualization of Orbital Involvement of Erdheim-Chester Disease on PET/CT
176. Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
177. Molecular Imaging and Therapy of Merkel Cell Carcinoma
178. Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer
179. FDG PET/CT Findings in a Rare Case of Giant Fibrovascular Polyp of the Esophagus Harboring Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma
180. Inadvertent Intra-arterial Injection of 123I-MIBG in a Patient With Metastatic Pheochromocytoma
181. Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
182. FDG PET/CT Detection of Intussusception Caused by Lymphoma in a Pediatric Patient
183. Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature
184. Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with 223Ra-Dichloride
185. Prevotella spp y Porphyromonas spp en adultos jóvenes con enfermedad periodontal
186. Split-Dose Technique for FDG PET/CT–guided Percutaneous Ablation: A Method to Facilitate Lesion Targeting and to Provide Immediate Assessment of Treatment Effectiveness
187. Repetitively dosed docetaxel and153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
188. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study.
189. Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT): Initial results from a phase I trial.
190. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).
191. Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial
192. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
193. Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.
194. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity Y- or Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
195. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
196. 18F-FDG Uptake in Metaphyseal Growth Arrest Lines
197. Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT).
198. A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.
199. Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results.
200. Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.